Will Chou, MD.

Will Chou, MD.

Company: Aruvant

Job title: CEO


Developing a Differentiated Gene Therapy for Sickle Cell Disease: Key Considerations 9:00 am

Aligning with regulatory requirements for quality of gene therapies, across CMC & clinical development Standing out from both a safety and efficacy perspective Developing therapies in a ‘crowded’ market – with respect to gene therapies in development and existing standards of careRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.